MLANA and melanoma: In contrast to clinical trial findings of MART-1-specific TCR therapy, NY-ESO-1-specific TCR-transduced lymphocytes had no off-target toxicities in melanoma patients due to the preferential expression of NY-ESO-1 on tumor cells and its absence in normal tissues [42].